Skip to main content

Table 1 Prevalence of anemia in stage 3–5 NDD-CKD Patients in 20% Medicare and commercially insured (MarketScan) datasets

From: Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States

  Medicare Commercially insured (MarketScan)
   Anemia prevalence (%), CKD stage   Anemia prevalence (%), CKD stage
Characteristics n, anemiaa 3–5 3 4 5 n, anemiaa 3–5 3 4 5
Overall 109,251 50.1 43.9 64.0 72.8 15,716 28.0 22.4 41.3 53.9
Age, years
 18–44 ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ 1724 25.9 19.6 34.9 50.4
 45–54 ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ 3755 27.0 21.4 40.1 50.6
 55–59 ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ 4450 28.5 23.0 41.5 56.4
 60–63 ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ 5787 28.9 23.3 44.2 56.8
 66–69 15,500 44.6 38.0 59.9 69.0 ─ ─ ─ ─ ─ ─ ─ ─ ─ ─
 70–74 25,212 47.0 40.7 62.5 70.9 ─ ─ ─ ─ ─ ─ ─ ─ ─ ─
 75–79 29,625 50.1 44.2 63.6 72.9 ─ ─ ─ ─ ─ ─ ─ ─ ─ ─
 80–85 38,914 55.1 49.2 67.0 76.5 ─ ─ ─ ─ ─ ─ ─ ─ ─ ─
Sex
 Men 50,615 46.9 41.1 60.3 69.5 7531 23.7 18.5 35.1 50.5
 Women 58,636 53.2 46.7 67.4 76.2 8185 33.6 27.5 48.5 58.3
Raceb
 White 87,617 48.9 42.9 62.9 71.9 ─ ─ ─ ─ ─ ─ ─ ─ ─ ─
 Black 15,263 57.9 51.0 70.5 75.2 ─ ─ ─ ─ ─ ─ ─ ─ ─ ─
 Other 6371 51.4 43.5 66.4 75.1 ─ ─ ─ ─ ─ ─ ─ ─ ─ ─
Comorbidity
 ASHD 57,070 59.0 53.0 70.0 78.4 3707 39.7 33.0 51.3 65.3
 CHF 44,239 66.9 61.1 74.9 82.4 3360 47.9 40.3 57.8 69.1
 CVA/TIA 25,814 62.6 56.9 73.1 79.8 1573 44.9 38.3 55.3 67.6
 PVD 38,868 62.8 57.0 72.2 80.6 2997 49.6 42.6 60.7 69.5
 Cardiac (other) 38,822 65.6 59.7 76.1 82.7 3688 48.5 41.5 60.7 67.9
 COPD 36,910 62.4 56.6 73.1 79.5 2467 43.5 37.6 54.1 67.2
 GI bleeding 13,773 87.1 83.9 92.4 93.3 1403 71.7 66.2 83.0 79.0
 Liver disease 4088 71.6 65.6 81.9 85.4 1118 52.2 44.9 60.5 70.3
 Dysrhythmia 47,814 61.1 55.3 71.3 79.7 3060 44.4 37.4 56.4 67.6
 Cancer 22,524 60.3 54.9 72.1 79.7 2227 41.7 35.3 57.8 69.2
 Diabetes 64,180 54.0 47.3 66.7 76.2 8246 33.7 27.4 46.4 59.1
 Hypertension 105,397 51.0 44.8 64.7 73.9 13,418 31.0 24.9 44.2 57.6
Inflammatory conditions
 Glomerulonephritis 6529 68.7 58.1 77.9 88.1 1229 44.1 34.7 52.8 75.0
 Chronic infections 2128 74.7 70.4 78.8 89.3 622 56.2 48.7 70.7 72.4
 Crohn’s disease 836 70.5 64.2 80.4 90.3 199 50.3 47.2 53.4 65.9
 Ulcerative colitis 912 71.4 66.4 82.4 87.7 176 55.0 48.9 62.0 83.8
 Hepatitis C 703 66.7 61.5 72.2 77.0 354 48.2 42.8 50.4 62.7
 Gout 17,862 59.0 50.8 70.5 80.8 1521 32.2 26.0 43.8 59.6
 Rheumatoid arthritis 5593 67.4 61.8 78.8 87.6 495 39.8 35.9 55.6 53.9
  1. ASHD atherosclerotic heart disease, CHF congestive/chronic heart failure, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CVA/TIA cerebrovascular accident/transient ischemic attack, GI gastrointestinal, NDD non-dialysis-dependent, PVD peripheral vascular disease
  2. aIn the row “Overall,” n is the total number of patients with anemia. In other rows, n represents the number of anemia patients in each subgroup; for example, the n of 57,070 in the row “ASHD” represents the number of anemia patients with comorbid ASHD
  3. bRace variable is not available in the MarketScan database